|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Orexin/Arch</i> mice also had increased REM sleep under baseline conditions but did not exhibit cataplexy, a sudden loss of muscle tone during wakefulness characteristic of NT1.
|
31628177 |
2019 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
To validate polysomnographic markers (sleep latency and sleep-onset REM periods [SOREMPs] at the Multiple Sleep Latency Test [MSLT] and nocturnal polysomnography [PSG]) for pediatric narcolepsy type 1 (NT1) against CSF hypocretin-1 (hcrt-1) deficiency and presence of cataplexy, as no criteria are currently validated in children.
|
31405906 |
2019 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these results demonstrate that DORA's potently increase NREM and REM sleep in mice via blockade of orexin signaling, and higher doses can cause cataplexy when co-administered with a likely rewarding stimulus.
|
31830270 |
2019 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we tested the long-standing hypothesis that muscle paralysis during cataplexy is caused by recruitment of the brainstem circuit that induces muscle paralysis during REM sleep.
|
31679942 |
2019 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considering that the CeA sends substantial GABAergic input to the LC, the present observation might serve as an anatomical substrate to support the potent hypnogenic role of MCH neurons in the LH regions during cataplexy and REM sleep.
|
29625116 |
2018 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cataplexy and sleep-onset REM sleep were significantly decreased in orexin knockout mice during and long after slow infusion of orexin (1 nmol/1 µL/h).
|
29784823 |
2018 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, the repeated nocturnal application of GHB in patients with narcolepsy improves the continuity of sleep, prolongs the latency to REM sleep and prevents cataplexy.
|
19654034 |
2009 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Narcoleptics were included if they had both excessive daytime sleepiness and clear-cut cataplexy (for the group with cataplexy), a mean sleep latency of less than 8 minutes and at least two sleep onset REM periods.
|
11833861 |
2002 |
|
Cataplexy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness and abnormal manifestations of REM sleep including cataplexy, sleep paralysis, and hypnagogic hallucinations.
|
9582188 |
1998 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, our results revealed that cataplexy onset corresponds to the emergence of adult-like REM sleep and to previously reported neuroanatomical and neurochemical abnormalities in canine narcolepsy.
|
9710528 |
1998 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
They demonstrated attacks of cataplexy and inappropriate periods of REM sleep during which they were unarousable.
|
8628463 |
1996 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA DR2 in narcolepsy with sleep-onset REM periods but not cataplexy.
|
1751625 |
1991 |
|
Cataplexy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Other important features are disturbed nocturnal sleep and abnormal manifestations of REM sleep such as cataplexy, sleep paralysis, and abnormal sleep-onset REM periods.Narcolepsy is not a rare condition.
|
2902604 |
1987 |